Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing its sole product candidate, BHB-1893. BHB-1893 is an oral small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy, a chronic disease where overactive proteins cause the heart muscle to thicken and obstruct blood flow. The company is developing the drug for both obstructive and non-obstructive forms of the disease. Braveheart licensed BHB-1893 from Jiangsu Hengrui and is responsible for its development and commercialization outside of Greater China. As a pre-revenue business, Braveheart funds operations through equity raises and intends to generate revenue through the sale of BHB-1893 as a branded prescription drug if it receives regulatory approval. Under the licensing agreement, the company will pay Hengrui royalties on net sales and various development and commercial milestone payments. Braveheart’s strategy centers on conducting global Phase 3 clinical trials, including LIONHEART-HCM and NOBLEHEART-HCM, to support regulatory submissions. The company designed BHB-1893 to provide relief of heart obstruction with a safety profile that allows for a simplified dosing regimen. Beyond its primary indications, Braveheart may also develop the candidate for heart failure with preserved ejection fraction based on data from trials currently ongoing in China.